DARE Daré Bioscience, Inc.: Long-Term Debt to Capital Coefficient

Symbol and logo of brand Daré Bioscience, Inc. (DARE)

Dare Bioscience, Inc. (DARE) generates revenue through the implementation of XACIATO and the development of long-term female contraceptives. The business model relies on outsourcing production and trials to minimize capital expenditures. The ratio of long-term liabilities to equity demonstrates the debt load dynamics, where the value of 0.00 reflects the metric's balance. Patent protection for hydrogels provides the company with a sustainable advantage in negotiations with partners.

DARE - Dare Bioscience Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Comprehensive metric breakdowns and analytics for Dare Bioscience, Inc. (DARE)

- price and consensus price forecast:
Quote Chart Dare Bioscience|DARE - Analyst Consensus Forecast
- market capitalization data:
Market Value Dare Bioscience|DARE - Enterprise Value
- book capitalization data:
Book Value per Share Daré Bioscience|DARE - Company Book Value|Market Value to Book Value darebioscience.com|DARE - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Dare Bioscience, Inc.|DARE - Long-Term Debt to Capital|Short-Term Debt to Capital darebioscience.com|DARE - Company Total Debt|Debt to Net Assets Ratio Dare Bioscience|DARE - Company Long-Term Liabilities|Company Current Liabilities Daré Bioscience
Initial company analysis:DARE Dare Bioscience
Core merchandise of Dare Bioscience, Inc.

Dare Bioscience, Inc. (DARE) invests in the development of unique non-hormonal women's health products. The long-term debt-to-equity ratio reflects the company's reliance on external borrowed financing. This coefficient measures the proportion of loans with a maturity exceeding one year relative to the market value of net assets. Analyzing the financial leverage indicator for long-term debt allows for an assessment of the risk of cash flow gaps. A low debt level confirms financial stability during the scaling of patented developments.

Competing companies

Long-Term Liabilities to Equity Organon & Co|TherapeuticsMD, Inc. (TXMD) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Palatin Corp (PTN)